{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:08:57Z","timestamp":1783177737943,"version":"3.54.6"},"reference-count":33,"publisher":"Japanese Circulation Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2026,3,10]]},"DOI":"10.1253\/circrep.cr-25-0264","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T22:09:09Z","timestamp":1766786949000},"page":"453-460","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Determinants and Prognostic Significance of Circulating Angiopoietin-Like Protein 3 Levels in Patients With Chronic Coronary Syndrome"],"prefix":"10.1253","volume":"8","author":[{"given":"Hiroki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunosuke","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinuko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichi","family":"Komaki","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Moribayashi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ideguchi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michikazu","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Statistics and Data Management, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Tsuruda","sequence":"additional","affiliation":[{"name":"Department of Hemo-Vascular Advanced Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kaikita","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>Eur Heart J<\/i> 2020; 41: 407\u2013477, doi:10.1093\/eurheartj\/ehz425.","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Matsuura Y, Kanter JE, Bornfeldt KE. Highlighting residual atherosclerotic cardiovascular disease risk. <i>Arterioscler Thromb Vasc Biol<\/i> 2019; 39: e1\u2013e9, doi:10.1161\/ATVBAHA.118.311999.","DOI":"10.1161\/ATVBAHA.118.311999"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Higuma T, Akashi YJ, Fukumoto Y, Obara H, Kakuma T, Asaumi Y, et al. Residual coronary risk factors associated with long-term clinical outcomes in patients with coronary artery disease treated with high- vs. low-dose statin therapy: REAL-CAD substudy. <i>Circ J<\/i> 2024; 88: 995\u20131003, doi:10.1253\/circj.CJ-23-0134.","DOI":"10.1253\/circj.CJ-23-0134"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Seiyama K, Oka A, Miyoshi T, Sudo Y, Takagi W, Ugawa S, et al. Impact of an intensive lipid-lowering therapy protocol on achieving target low-density lipoprotein cholesterol levels in patients with acute coronary syndrome. <i>Circ Rep<\/i> 2025; 7: 131\u2013138, doi:10.1253\/circrep.CR-24-0071.","DOI":"10.1253\/circrep.CR-24-0071"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Yoshikawa M, Honda A, Arashi H, Shibahashi E, Otsuki H, Kawada-Watanabe E, et al. Addition of ezetimibe to intensive lipid-lowering therapy is associated with a lower incidence of heart failure in patients with acute coronary syndrome. <i>Circ J<\/i> 2024; 88: 1819\u20131824, doi:10.1253\/circj.CJ-24-0536.","DOI":"10.1253\/circj.CJ-24-0536"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Sheng F, Miyawaki K, Osada N, Tanaka S, Liu Z, Shinke T. Efficacy and safety of evolocumab in improving low-density lipoprotein cholesterol (LDL-C) levels in a Japanese population: Systematic review and meta-analysis. <i>Circ Rep<\/i> 2025; 7: 886\u2013895, doi:10.1253\/circrep.CR-25-0109.","DOI":"10.1253\/circrep.CR-25-0109"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Kurobe M, Baba K, Nunohiro T, Ishizaki M, Furudono S, Nakata T, et al. Impact of implementation of a region-wide low-density lipoprotein cholesterol management clinical pathway for the secondary prevention of acute myocardial infarction. <i>Circ J<\/i> 2024; 88: 1825\u20131832, doi:10.1253\/circj.CJ-24-0338.","DOI":"10.1253\/circj.CJ-24-0338"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Minami Y, Ikari Y, Harada M, Suzuki H, Fukui K, Ako J, et al. Global low-density lipoprotein cholesterol targets for patients with acute coronary syndrome: Current guidelines and clinical pathways. <i>Circ J<\/i> 2026; 90: 266\u2013273, doi:10.1253\/circj.CJ-25-0365.","DOI":"10.1253\/circj.CJ-25-0365"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Kim K, Ginsberg HN, Choi SH. New, novel lipid-lowering agents for reducing cardiovascular risk: Beyond statins. <i>Diabetes Metab J<\/i> 2022; 46: 817\u2013818, doi:10.4093\/dmj.2022.0198.","DOI":"10.4093\/dmj.2022.0198"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Tomlinson B, Wu QY, Zhong YM, Li YH. Advances in dyslipidaemia treatments: Focusing on ApoC3 and ANGPTL3 inhibitors. <i>J Lipid Atheroscler<\/i> 2024; 13: 2\u201320, doi:10.12997\/jla.2024.13.1.2.","DOI":"10.12997\/jla.2024.13.1.2"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 deficiency and protection against coronary artery disease. <i>J Am Coll Cardiol<\/i> 2017; 69: 2054\u20132063, doi:10.1016\/j.jacc.2017.02.030.","DOI":"10.1016\/j.jacc.2017.02.030"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. <i>N Engl J Med<\/i> 2020; 383: 711\u2013720, doi:10.1056\/NEJMoa2004215.","DOI":"10.1056\/NEJMoa2004215"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. <i>N Engl J Med<\/i> 2024; 391: 913\u2013925, doi:10.1056\/NEJMoa2404147.","DOI":"10.1056\/NEJMoa2404147"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Morinaga J, Zhao J, Endo M, Kadomatsu T, Miyata K, Sugizaki T, et al. Association of circulating ANGPTL 3, 4, and 8 levels with medical status in a population undergoing routine medical checkups: A cross-sectional study. <i>PLoS One<\/i> 2018; 13: e0193731, doi:10.1371\/journal.pone.0193731.","DOI":"10.1371\/journal.pone.0193731"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. <i>In<\/i>: Manual of hypertension of the European Society of Hypertension. CRC Press, 2019; 543\u2013627.","DOI":"10.1201\/9780429199189-75"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>Eur Heart J<\/i> 2020; 41: 255\u2013323, doi:10.1093\/eurheartj\/ehz486.","DOI":"10.1093\/eurheartj\/ehz486"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. George C, Matsha TE, Korf M, Zemlin AE, Erasmus RT, Kengne AP. The agreement between fasting glucose and markers of chronic glycaemic exposure in individuals with and without chronic kidney disease: A cross-sectional study. <i>BMC Nephrol<\/i> 2020; 21: 32, doi:10.1186\/s12882-020-1697-z.","DOI":"10.1186\/s12882-020-1697-z"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. <i>World J Hepatol<\/i> 2021; 13: 1688\u20131698, doi:10.4254\/wjh.v13.i11.1688.","DOI":"10.4254\/wjh.v13.i11.1688"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Jasiewicz M, Siedlaczek M, Kasprzak M, Gorog DA, Jilma B, Siller-Matula J, et al. Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials? <i>Cardiol J<\/i> 2023; 30: 747\u2013752, doi:10.5603\/CJ.a2021.0081.","DOI":"10.5603\/CJ.a2021.0081"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Zhang Y, Yan C, Dong Y, Zhao J, Yang X, Deng Y, et al. ANGPTL3 accelerates atherosclerotic progression via direct regulation of M1 macrophage activation in plaque. <i>J Adv Res<\/i> 2025; 70: 125\u2013138, doi:10.1016\/j.jare.2024.05.011.","DOI":"10.1016\/j.jare.2024.05.011"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Ling P, Zheng X, Luo S, Ge J, Xu S, Weng J. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside. <i>Diabetes Obes Metab<\/i> 2021; 23: 2020\u20132034, doi:10.1111\/dom.14450.","DOI":"10.1111\/dom.14450"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Chen PY, Gao WY, Liou JW, Lin CY, Wu MJ, Yen JH. Angiopoietin-like protein 3 (ANGPTL3) modulates lipoprotein metabolism and dyslipidemia. <i>Int J Mol Sci<\/i> 2021; 22: 7310, doi:10.3390\/ijms22147310.","DOI":"10.3390\/ijms22147310"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Reeskamp LF, Tromp TR, Huijgen R, Stroes ESG, Hovingh GK, Grefhorst A. Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation. <i>Atherosclerosis<\/i> 2020; 315: 68\u201375, doi:10.1016\/j.atherosclerosis.2020.11.013.","DOI":"10.1016\/j.atherosclerosis.2020.11.013"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J, et al. Natriuretic peptides: Role in the diagnosis and management of heart failure: A scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. <i>J Card Fail<\/i> 2023; 29: 787\u2013804, doi:10.1016\/j.cardfail.2023.02.009.","DOI":"10.1016\/j.cardfail.2023.02.009"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Ogawa T, de Bold AJ. Brain natriuretic peptide production and secretion in inflammation. <i>J Transplant<\/i> 2012; 2012: 962347, doi:10.1155\/2012\/962347.","DOI":"10.1155\/2012\/962347"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Shimamura M, Matsuda M, Yasumo H, Okazaki M, Fujimoto K, Kono K, et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. <i>Arterioscler Thromb Vasc Biol<\/i> 2007; 27: 366\u2013372, doi:10.1161\/01.ATV.0000252827.51626.89.","DOI":"10.1161\/01.ATV.0000252827.51626.89"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Qiu G, Hill JS. Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages. <i>J Lipid Res<\/i> 2007; 48: 2112\u20132122, doi:10.1194\/jlr.M600510-JLR200.","DOI":"10.1194\/jlr.M600510-JLR200"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Tada H, Kobayashi J, Kawashiri MA, Miyashita K, Nohara A, Inazu A. Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy. <i>Lipids Health Dis<\/i> 2016; 15: 66, doi:10.1186\/s12944-016-0238-z.","DOI":"10.1186\/s12944-016-0238-z"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Mehta N, Qamar A, Qu L, Qasim AN, Mehta NN, Reilly MP, et al. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits. <i>Arterioscler Thromb Vasc Biol<\/i> 2014; 34: 1057\u20131063, doi:10.1161\/ATVBAHA.113.302802.","DOI":"10.1161\/ATVBAHA.113.302802"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Silbernagel G, Chen YQ, Li H, Lemen D, Wen Y, Zhen EY, et al. Associations of circulating ANGPTL3, C-terminal domain-containing ANGPTL4, and ANGPTL3\/8 and ANGPTL4\/8 complexes with LPL activity, diabetes, inflammation, and cardiovascular mortality. <i>Circulation<\/i> 2025; 151: 218\u2013234, doi:10.1161\/CIRCULATIONAHA.124.069272.","DOI":"10.1161\/CIRCULATIONAHA.124.069272"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Lv Q, Jiao X, Yu H, Sun Q, Li F, Wang Y, et al. ANGPTL3 and cardiovascular outcomes in patients with acute coronary syndrome and obstructive sleep apnea. <i>J Am Heart Assoc<\/i> 2022; 11: e025955, doi:10.1161\/JAHA.122.025955.","DOI":"10.1161\/JAHA.122.025955"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Opstal TSJ, Nidorf SM, Fiolet ATL, Eikelboom JW, Mosterd A, Bax WA, et al. Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial. <i>Int J Cardiol<\/i> 2023; 372: 1\u20135.","DOI":"10.1016\/j.ijcard.2022.12.026"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Geladari E, Tsamadia P, Vallianou NG. ANGPTL3 inhibitors: Their role in cardiovascular disease through regulation of lipid metabolism. <i>Circ J<\/i> 2019; 83: 267\u2013273, doi:10.1253\/circj.CJ-18-0442.","DOI":"10.1253\/circj.CJ-18-0442"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/3\/8_CR-25-0264\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:20:36Z","timestamp":1773458436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/3\/8_CR-25-0264\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-25-0264","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"CR-25-0264"}}